What's New
-
New
Position Paper "Toward Advancing and Increasing the Value of Medical and Pharmaceutical Products Co-Created with Patients" - Patient-Reported Outcome (PRO) Evaluation as a Permanent
is now available. -
New
Position Paper "Survey of Domestic Emerging Pharmaceutical Companies (EBPs) with Developed Products" is now available.
is now available. -
New
Policy Research Institute News No.76 is now available.
Pick Up
Policy Research Institute News No.76 is now available.
Summary of Policy Research Institute News No.76 is here.
This issue includes the following
-
Comparison of New Drug Approval Status in Japan, the U.S., and Europe (2024)
Mariko Togashi, Senior Researcher, Pharmaceutical Industry Policy Institute
-
The Number of New Drugs in the Development Pipeline in the U.S.
Current Position of Drug Discovery Research in Japan
Chie Yoshiura, Senior Researcher, Pharmaceuticals & Industrial Policy Research Institute
Kiyoshi Morimoto, Senior Researcher, Pharmaceuticals & Industrial Policy Research Institute
Daisuke Kanai, Senior Research Fellow, Pharmaceuticals & Bioindustrial Policy Institute -
Survey of Alliances and Acquisitions into the Preclinical Stage
-Comparison between Japan and other countries-.
Senior Research Fellow, Pharmaceuticals and Industrial Policy Research Institute (PIIPRI)
Kiyoshi Morimoto, Senior Research Fellow, Pharmaceuticals & Industrial Policy Research Institute (PIIPRI)
Kiyoshi Morimoto, Senior Research Fellow, Pharmaceuticals and Industrial Policy Research Institute (PIIPRI) -
With products in development
Survey of Japanese Emerging Biopharmaceutical Companies (EBPs) with Developed Products
Kiyoshi Morimoto, Senior Researcher, Pharmaceuticals & Industrial Policy Research Institute
Kiyoshi Morimoto, Senior Research Fellow, Pharmaceuticals and Industrial Policy Research Institute (PIIPRI)
Senior Research Fellow, Pharmaceuticals and Industrial Policy Research Institute Daisuke Kanai -
CDMO Utilization Environment in Japan
Chie Yoshiura, Senior Research Fellow, Pharmaceuticals and Industrial Policy Research Institute (PIIPRI)
-
Systematic Review of Patient-Reported
Benefits and Challenges of Patient-Reported Outcome Measure (PROM) Interventions from a Systematic Review
Shinji Tsubakihara, Senior Researcher, Pharmaceuticals and Industrial Policy Research Institute (PIIPRI)
Takahiro Shiraishi, Senior Research Fellow, Pharmaceuticals and Industrial Policy Research Institute (PIIPRI)
Senior Research Fellow, Pharmaceuticals and Industrial Policy Research Institute (PIIPRI) -
Trends in the Calculation of New Drugs, Focusing on Correction Additions
-Trends before and after the 2024 NHI drug price reform (survey through August 2025)
Kyumi Yoshino, Senior Researcher, Pharmaceutical and Industrial Policy Research Institute (PIIPRI)
